JNJ-56136379(HBV衣壳组装调节剂)在慢性HBV感染患者中的1期研究:耐受性与抗病毒活性
该1期双盲研究纳入57例无肝硬化的初治慢性HBV感染者(74%为HBeAg阴性),随机接受JNJ-6379(25mg、75mg、150mg、250mg,25mg组含100mg负荷剂量)或安慰剂每日一次共4周,随访8周。结果显示各剂量组耐受性良好,暴露随剂量增加且呈时间线性药代动力学,HBV-DNA和HBV-RNA较基线下降,第29天32%患者HBV-DNA低于定量下限,HBsAg无临床显著变化。
要点
- JNJ-6379各剂量组耐受性良好,治疗期无严重不良事件报告。
- JNJ-6379暴露随剂量增加,呈时间线性药代动力学。
- 各剂量组HBV-DNA和HBV-RNA较基线下降,不依赖基因型和HBeAg状态。
核心结论
- 在初治慢性HBV感染患者的1期研究中,JNJ-6379所有测试剂量耐受性良好,呈剂量依赖性药代动力学,并具有强效抗病毒活性。
- 研究结果支持开展2a期研究评估JNJ-6379单用或联合核苷(酸)类似物治疗慢性HBV感染,该研究正在进行中。
研究设计与样本
- 双盲研究纳入57例无肝硬化的初治慢性HBV感染者,其中74%为HBeAg阴性。
- 患者随机接受JNJ-6379 25mg(100mg负荷剂量)、75mg、150mg、250mg或安慰剂每日一次共4周,随访8周。
主要发现
- 治疗期无严重不良事件报告;JNJ-6379组3例(7%)发生3级不良事件,安慰剂组无。
- 3级不良事件中1例(150mg组)另出现孤立性4级丙氨酸氨基转移酶升高并导致停药。
- JNJ-6379暴露随剂量增加,呈时间线性药代动力学。
- 第29天,41例中13例(32%)HBV-DNA低于定量下限;HBsAg水平未见临床显著变化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: JNJ-56136379 (JNJ-6379), a capsid assembly modulator that blocks hepatitis B virus (HBV) replication, was well tolerated and demonstrated dose-proportional pharmacokinetics in healthy participants in part 1 of its first clinical trial. In part 2, we have evaluated the safety, pharmacokinetics, and antiviral activity of multiple doses of JNJ-6379 in patients with chronic HBV infection. METHODS: We performed a double-blind study of 57 treatment-naïve patients with HB e antigen-positive or -negative (74%) chronic HBV infection without cirrhosis. Patients were randomly assigned to groups given JNJ-6379 at 25 mg (100 mg loading dose), 75 mg, 150 mg, or 250 mg or placebo daily for 4 weeks with an 8-week follow-up period. RESULTS: Twenty-three (56%) of 41 patients given JNJ-6379 had at least 1 adverse event (AE) during treatment, compared with 10 (63%) of 16 patients given placebo. No serious AEs were reported during the treatment period. Three patients (7%) given JNJ-6379 vs none given placebo had grade 3 AEs; of these, 1 patient (150 mg) also had an isolated grade 4 increase in the level of alanine aminotransferase that led to treatment discontinuation. JNJ-6379 exposure increased with dose, with time-linear pharmacokinetics. HBV-DNA and HBV-RNA decreased from baseline in patients receiving all doses of JNJ-6379, independently of viral genotype and HB e antigen status. On day 29, 13 (32%) of 41 patients had levels of HBV DNA below the lower limit of quantification. No clinically significant changes in levels of HB surface antigen were observed. CONCLUSIONS: In a phase 1 study of treatment-naïve patients with chronic HBV infection, all doses tested of JNJ-6379 were well tolerated, showed dose-dependent pharmacokinetics, and had potent antiviral activity in patients with CHB. The findings support a phase 2a study to evaluate JNJ-6379 ± nucleos(t)ide analogs in patients with chronic HBV infection, which is under way. ClinicalTrials.gov identifier: NCT02662712.
引用
- Zoulim F, Lenz O, Vandenbossche JJ, et al. JNJ-56136379, an HBV Capsid Assembly Modulator, Is Well-Tolerated and Has Antiviral Activity in a Phase 1 Study of Patients With Chronic Infection. Gastroenterology. 2020. PMID: 32343960. doi:10.1053/j.gastro.2020.04.036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。